Dan Shelly

Vice President of Business Development and Alliances • Prescient Therapeutics

Daniel Shelly, Ph.D., MBA is Vice President of Business Development and Alliances at Prescient Therapeutics where he is responsible for advancing a next-generation, modular, and post-infusion controllable CAR-Immune cell therapy platform along with small molecule targeted therapies. Previously, he was Director of Global Business Development and Strategic Partnerships for the global non-profit PATH, where he was the Co-Lead for the COVID-19 task force. He has over 19 years of biopharmaceutical BD licensing and alliance management experience. He is also an adjunct professor in the Master’s in Clinical Drug Development program at the University of Cincinnati’s College of Pharmacy.

Also Speaking

James Miskin

Chief Technical Officer  • Oxford BioMedica (UK) Ltd

Wilson Bryan

Director, Office of Tissues and Advanced Therapies • FDA

Andreas Kouri

Senior Vice President, Supply Chain Strategic Operations • ElevateBio

Event Info


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.